Cathay Biotech Inc.

688065

CNE100004447

Cathay Biotech Inc is a China-based company engaged in research, development, production and sales of biobased materials. The Company's primary products are biological long-chain dibasic acids and bio-based polyamide series, including lauric acid and brazilian acid, which are used in long-chain polyamides, fragrances, hot melt adhesives, lubricants, powder coatings and other areas. The Company sells its products to domestic and overseas markets.

Sector

Specialty Chemicals

Calendar

2024-03-25 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Cathay Biotech Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

52.05CNY

Average target price

67.18CNY

Spread / Average Target

+29.06%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Industrial Biotechnology Chemicals

	1st Jan change	Capi.
CATHAY BIOTECH INC.	-15.08%	4 239 M $
NOVOZYMES A/S	+2.39%	14 399 M $
BORREGAARD ASA	+13.16%	1 570 M $
PUYANG HUICHENG ELECTRONIC MATERIAL CO., LTD.	-37.56%	691 M $
HENAN JINDAN LACTIC ACID TECHNOLOGY CO.,LTD.	-5.59%	519 M $
BIO-ON S.P.A.	-81.65%	216 M $
CHEMCON SPECIALITY CHEMICALS LIMITED	-6.93%	122 M $
I-TECH AB	0.00%	61 M $

Industrial Biotechnology Chemicals

End-of-day quote Shanghai Stock Exchange Other stock markets 06:00:00 2023-12-07 pm EST			5-day change	1st Jan Change
52.05 ^CNY	-1.29%		-3.81%	-15.08%

Oct. 30	Cathay Biotech Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	CI
Sep. 18	Cathay Biotech Inc.(XSSC:688065) added to S&P Global BMI Index	CI

Cathay Biotech Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	Oct. 30	CI
Cathay Biotech Inc.(XSSC:688065) added to S&P Global BMI Index	Sep. 18	CI
Cathay Biotech Inc.(XSSC:688065) added to FTSE All-World Index	Sep. 18	CI
Cathay Biotech Inc. announces an Equity Buyback for CNY 100 million worth of its shares.	Aug. 17	CI
Cathay Biotech Inc. authorizes a Buyback Plan.	Aug. 16	CI
Cathay Biotech Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	Aug. 03	CI
Cathay Biotech Forms Business Cooperation Agreement	Jun. 27	MT
HBM Healthcare's Portfolio Company Cathay Biotech to Sell Shares for CNY6.6 Billion	Jun. 26	MT
Cathay Biotech Inc. announced that it expects to receive CNY 6.599999958 billion in funding from China Merchants Group Limited	Jun. 24	CI
Cathay Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	Apr. 26	CI
Cathay Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	Feb. 27	CI
MoleculeMind announced that it has received CNY 100 million in funding from Lenovo Capital and Incubator Group, Sequoia China Investment Management LLP, Cathay Biotech Inc.	Feb. 19	CI
Cathay Biotech CFO Resigns	Jan. 10	MT
Tranche Update on Cathay Biotech Inc.'s Equity Buyback Plan announced on March 30, 2022.	Nov. 30	CI
Cathay Biotech Inc.'s Equity Buyback announced on March 30, 2022, has expired with 1,133,035 shares, representing 0.19% for CNY 94.57 million.	Nov. 29	CI
Cathay Biotech Inc. announced that it has received $28 million in funding from Eight Roads Ventures, Sequoia China Investment Management LLP, Source Code Capital, Bits x Bites	Nov. 06	CI
Cathay Biotech Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	2022	CI
HBM Healthcare Swings To Fiscal H1 Loss On Reduced Share Price Of Portfolio Company Cathay Biotech	2022	MT
Tranche Update on Cathay Biotech Inc.'s Equity Buyback Plan announced on March 30, 2022.	2022	CI
Cathay Biotech’s H1 Profit Rises 7.7% as Revenue Climbs 13.5%	2022	MT
Cathay Biotech Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	2022	CI
Tranche Update on Cathay Biotech Inc.'s Equity Buyback Plan announced on March 30, 2022.	2022	CI
Cathay Biotech Inc. announced that it has received $15 million in funding from Source Code Capital, Sherpa Venture Capital, Bits x Bites	2022	CI
Cathay Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	2022	CI
Tranche Update on Cathay Biotech Inc.'s Equity Buyback Plan announced on March 30, 2022.	2022	CI